Monalizumab

莫那利珠单抗

Report date: 2026/05/07 20:00:36
First In Class

Base Information

Drug NameMonalizumab
Drug Alias Name莫那利组单抗NN-8765IPH-2201NNC-0141-0000-0100NNC 0141-0000-0100 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionNK cell lectin-like receptor subfamily C member 1 antagonists
TargetsNK cell lectin-like receptor subfamily C member 1
Therapy Area/IndicationsEsophageal adenocarcinomaOral Squamous Cell CarcinomaSolid tumours +[22] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[32] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesThe Netherlands Cancer InstituteInnate PharmaAstrazeneca Plc +[10] 
Inactive CompaniesJules Bordet InstituteInstitut Paoli-Calmettes
Active IndicationsSolid tumoursMyelodysplastic SyndromesUrinary Bladder Neoplasms +[11] 
Inactive IndicationsEsophageal adenocarcinomaOral Squamous Cell CarcinomaInflammation +[11] 

Other Information

ATC CodeN/A
Related LinksN/A